Biomedical subjects

M D Aliev

Publications and source records attributed to M D Aliev.

21 records · Page 2Linked to original sources

PubMedDate not supplied

[Bone tumors and androgen metabolism].

The paper provides data of comparative assessment of activity of the key enzymes in metabolism of androgens in various morphological variants of sarcomas and benign bone tumors in 46 patients within the age range from 15 to 61, which were under treatment in the ORC named after N. N. Blokhin, RAMS, from 1996 to 1997. On the basis on publications and our own research results we can suggest that malignant human bone tumors of various histogenesis are subject to metabolic processes of testosterone (T), the principal androgen regulator in the bone tissue, as well as formation in bones of 5 alpha-dihydrotestosterone (DHT). One cannot exclude a possibility that metabolism of androgen in bone tissues is directed towards formation of other androgens (in addition to DHT), which may participate in the bone tissue regulation, for instance, 3 alpha- and 3 beta-diols; specific activity of the latter has recently been intensively scrutinized. One can expect that further research shall disclose the clinical significance of metabolism of androgens and of individual androgens in human bone formations.

Adolescent↗

PubMedDate not supplied

[Computed tomography of children with dysplasia of the hip joint].

The hip joints in 10 children were investigated with computerized tomography (CT). The method permitted the determination of the geometry of hip joints. It was used for a study of the pathogenesis of aseptic necrosis at early stages of its development in children with congenital dysplasia of the hip joint at early stages of disease. CT made it possible to establish anteversion of the cotyloid cavity, its degree, the shape and structure of the anterior and posterior wall of the cotyloid cavity, and a shift of the proximal hip end anteriorly in combination with the above changes in the whole hip joint.

Child↗

PubMedDate not supplied

[Selenium in blood serum and in tumors of patients with benign and malignant bone neoplasms].

The content of selenium in the serum and bones was compared in persons having no neoplasms and in patients with malignant and benign bone tumors. The mean level of selenium in the healthy femoral bone was 81 micrograms/kg, with more predominant accumulation in the epiphysis than in the metaphysis and diaphysis and with higher concentrations in the periosteum than in the cambial layer. The normal mean bone/serum selenium ratio was 0.74. This index varied 0.8 to 5.1 in patients with benign tumors and 2.3 to 10.0 in those with malignant tumors. Benign tumors were characterized by significant multiple variations of tumor selenium levels depending on the type of an abnormality with maximally observed values in giant-cell tumor. In patients with various osteosarcomas, the mean selenium content was decreased to 71% in the serum and increased up to 300% in the tumor. The examination of the impact of the type of non-adjuvant therapy on serum selenium levels in patients with bone tumors indicated a negative selenium effect in the application of radiation therapy and a positive selenium effect in the transfusion of bone marrow suspension and in the use of platidium or SAR-regimen therapy.

Adult↗